Practical Neurology

The painting on the cover of our May/June issue was created by Isabella Sammut, a 17-year-old who uses art to raise awareness for #headache disorders and advocate for more research and better treatments. ow.ly/O8tA50Zp5T5 @Ahsheadache @amfmigraine @nhf @aanmember

Federal protections increasingly recognize #migraine-related disability in schools, the workplace, and disability programs. An article by Nina Riggins, MD, PhD (@NinaRiggins) and Lorenzo Paris, JD examines how Section 504, FMLA, and SSDI/SSI apply to headache care—and why clear clinical documentation matters. ow.ly/ge7i50ZoENI @ahsheadache @amfmigraine @nhf @AANmember

The @US_FDA approved #Leqembi #IQLIK as a once-weekly subcutaneous initiation dose for adults with early #Alzheimer disease, expanding use beyond maintenance therapy. ow.ly/8uNj50ZoCXp @eisaiUS @Biogen @alzassociation @AANmember

New long-term APOLLOE4 data suggest sustained slowing of clinical decline with investigational oral #amyloid-oligomer inhibitor #valiltramiprosate (ALZ-801) in APOE4/4 participants with MCI due to early #Alzheimer's. ow.ly/gKFo50Zo1N9 @AlzAssociation @Alzheon #AAIC26

A high-performance blood-based p-tau217/Aβ1-42 test significantly improved neurologists' diagnostic concordance for early #Alzheimer's in study results presented at #AAIC26. ow.ly/mOAc50Zo1tQ @alzassociation @AANmember

When #Migraine and functional neurologic disorder coexist, accurate diagnosis and coordinated care are essential. Read an article by Mia Minen, MD (@MiaMinenMD), Uma-Devi Budhu, and W Curt LaFrance, Jr, MD, MPH discussing clinical recognition, patient education, and multidisciplinary management. ow.ly/I5yM50ZnEeW @FNDSociety @Ahsheadache @nyugrossman @VAProvidence @RIHospital @BrownNeurology

Plasma #GFAP may reflect #amyloid pathology—but not independently predict #Alzheimer's progression. In data from 2 longitudinal cohorts reported at #AAIC26, associations with #tau pathology and #neurodegeneration were no longer significant after accounting for amyloid burden. ow.ly/TiCC50ZnyO8 #Dementia #Biomarkers #Neurology #NeuroTwitter @alzassociation @UsAgainstAlz

In results of a real-world study presented at #AAIC26, subcutaneous #Leqembi reduced treatment burden and improved patient experience in early #Alzheimer's. ow.ly/JcuF50ZnyM7 @AlzAssociation @EisaiUS @Biogen #lecanemab

#JanusKinase inhibitors are emerging as a new therapeutic option for #GiantCellArteritis. A review article by V Moynihan, MBBS and A R Carey, MD (@DrewCareyMD) examines the science, clinical evidence, and practical considerations shaping their role in GCA care. ow.ly/tmj250ZmKEs @HopkinsMedicine @NANOSTweets @AANmember

CraniUS Therapeutics (@crani_us) received an initial $1.1 million @NIH Blueprint MedTech award to support development of #NeuroPASS for recurrent #glioblastoma, with the possibility to receive up to $4 million in total funding. ow.ly/awqO50Zmynx @AANmember @Neuroonc

#Eptinezumab combined with patient education reduced monthly #migraine days more than placebo + education in adults with chronic migraine and medication-overuse #headache. ow.ly/iaP450Zmyfn @AANmember @ahsheadache @vyeptiHCP @LundbeckUS

🧠🎙️ @BillNye the Science Guy speaks with @PracticalNeuro to share his family's experiences with #SpinocerebellarAtaxia and reflect on living with the knowledge of his own genetic risk. He is joined by Lauren Moore, PhD (@NAF_Ataxia) who discusses #ataxia care, emerging therapies, and what's ahead for patients and clinicians in this episode of Amplifying the Patient Journey. Listen now: ow.ly/O9H350ZmeL6

Clinical diagnosis of #parkinsonian disorders remains challenging. An autopsy-confirmed study found 10%–20% misdiagnosis rates and frequent mixed pathology, highlighting the potential role of genetics and #neuropathology in improving diagnostic precision. ow.ly/H8aI50ZlPyW @JAMANeurology @Parkinsondotorg @movedisorder @AANmember

Patient-led organizations have transformed the landscape of #ClusterHeadache care—from advancing research and improving diagnosis to expanding treatment access and peer support. Read an article by Dr. Pyland, Dr. Gottschalk (@CGottschalkMD), & Anna Williams (@Cluster_buster) exploring cluster #headache advocacy: ow.ly/rMVp50ZllJ4 @ahsheadache @amfmigraine @nhf @AANmember @AtriumHealthWFB @YaleMed

Prior #TBI may reduce the diagnostic accuracy of #Alzheimer's blood #biomarkers, according to findings from a cross-sectional diagnostic test study published in @JAMANeuro. ow.ly/xJF650ZllvE @alzassociation @AANmember @BIAamerica

The @US_FDA granted Breakthrough Device Designation to the V-Link system for reducing cerebral #vasospasm in adults with aneurysmal subarachnoid hemorrhage receiving ICU care. ow.ly/zJkG50ZkSBx @American_Heart @AANmember @American_Stroke

#Pixclara, an investigational PET imaging agent for #glioma, has been accepted for @US_FDA review, with a target action date of Sept. 11, 2026. ow.ly/EQH850Zjuif @TelixPharma @AANmember @NeuroOnc

The @US_FDA granted #510(k) clearance for the #PoNS System, a noninvasive #neuromodulation device applied to the tongue, to treat dynamic gait deficit due to chronic #stroke symptoms. ow.ly/Gmlb50ZjugO @BionessLiveOn @American_Stroke @AANmember

The @US_FDA has expanded the indication for #Xeomin (#incobotulinumtoxinA) to include children and adolescents aged ≥2 years with upper limb spasticity associated with #CerebralPalsy. ow.ly/1YQY50Zjufi @MerzTx_US @yourcpf

Every health system faces different challenges when implementing early #Alzheimer's detection. In the newest episode of our #Neurology Deep Dive podcast series, Elyse Perweiler, RN, MPP & Tim MacLeod, PhD, discuss how peer learning networks help teams share solutions, refine workflows, and learn from one another. ow.ly/bFQc50ZjucP @RowanVirtuaSOM @DavosAlzheimers @alzassociation @AANmember